内容概要：量子精密测量借助量子态高敏感性突破经典测量极限，涵盖时频基准、电磁场测量、重力测 量等多个方向，已逐步从实验室走向通信、导航、能源、医疗等实际应用领域，展现出"超精密、高稳 定、抗干扰"的核心优势。中国科学院自主研发的高精度原子钟已达国际先进水准，量子测量产品精度 惊人。中国量子精密测量行业在技术创新和政策支持下蓬勃发展，市场应用呈现迅速扩张的趋势。我国 量子精密测量主要应用于军事国、民用领域（能源、医疗、通信）、科学等领域。2024年我国量子精密 测量市场规模增长至2.95亿美元，在军事国防领域量子精密测量技术市场占据58.98%的市场份额，其次 为民用与科学领域合计约占10.51%。2025年我国量子精密测量市场规模约为4.35亿美元，预计2026年有 望达到5.2亿美元，2035年有望达到10.53亿美元。 上市企业：国盾量子(688027.SH)、天奥电子(002935.SZ)、中国船舶(600150.SH)、西部超导 (688122.SH)、光韵达(300227.SZ)、国睿科技(600562.SH)、天奥电子[002935] 关键词：量子精密测量行业政策、量子精密测量产业链、量子精密测量 ...

Core Viewpoint - Guoyi Quantum has successfully broken the foreign monopoly in high-end scientific instruments and is planning an IPO on the Sci-Tech Innovation Board to support the localization of high-end scientific instruments in China [1]. Group 1: Company Overview - Guoyi Quantum, established in December 2016, is recognized as a national-level specialized and innovative "little giant" enterprise and was included in the list of Chinese unicorn companies in 2024 [5]. - The company focuses on the research and development of high-end scientific instruments, providing essential equipment for quantum technology, materials science, chemical engineering, biomedicine, and advanced manufacturing [10]. - Guoyi Quantum has developed products that have broken the long-standing monopoly of international giants in certain segments of the domestic instrument market, achieving performance metrics that meet or exceed international competitors [10]. Group 2: Leadership and Control - The actual controllers of Guoyi Quantum are He Yu and Rong Xing, who collectively control 34.87% of the voting rights through various indirect holdings [3]. - He Yu, a notable figure from the University of Science and Technology of China (USTC), has held multiple leadership roles and has been recognized with various awards for his contributions to the industry [4]. - Rong Xing, also a USTC alumnus, has a distinguished academic background and has served in various significant positions within the scientific community [4]. Group 3: Financial Performance - Guoyi Quantum's revenue has shown significant growth, with figures of 151.45 million, 400 million, 501 million, and 171 million yuan for the years 2022 to 2025, reflecting year-on-year growth rates of 163.78% and 25.49% for 2023 and 2024 respectively [13]. - Despite the revenue growth, the company has not yet achieved profitability, with net losses reported at -168 million, -169 million, -104 million, and -74 million yuan for the same period [14]. - The company anticipates turning a profit in 2026, contingent on factors such as product strength, market expansion, and cost control [15]. Group 4: Market Position and Competition - The scientific instrument market has been dominated by international firms like Thermo Fisher, Danaher, and Agilent, which have established a strong presence over decades [16]. - Domestic manufacturers, including Guoyi Quantum, are gradually gaining recognition and breaking the monopoly of these international giants through technological advancements [16]. - Guoyi Quantum faces challenges in enhancing brand recognition and overcoming market penetration barriers due to the long-standing dominance of foreign brands [16][17].

Core Viewpoint - The article highlights the growing interest and investment in quantum technology, particularly in the context of China's "14th Five-Year Plan," which includes quantum technology as a strategic growth point for the new economy. The IPO wave in the quantum technology sector is beginning, with Guoyi Quantum Technology (Hefei) Co., Ltd. filing for an IPO on the Sci-Tech Innovation Board [1]. Company Overview - Guoyi Quantum focuses on the research and development of high-end scientific instruments, providing advanced scientific equipment and solutions for various fields, including quantum technology, materials science, and biomedicine [1][4]. - The company has launched several products, including electron paramagnetic resonance spectrometers and scanning electron microscopes, breaking the long-standing dominance of international giants in certain segments of the domestic market [4]. Revenue Composition - From 2022 to the first half of 2025, the revenue share from quantum information technology and spin resonance decreased from 49.32% to 25.26%, while the revenue share from electron microscope series increased from 24.46% to 56.02% [5][6]. - The company’s revenue figures for the years 2022 to 2025 (first half) are approximately 151 million, 400 million, 501 million, and 171 million respectively, with corresponding net losses of approximately -129 million, -146 million, -86 million, and -76 million [11]. Market Dynamics - The global market for laboratory analytical instruments is projected to grow from $82.95 billion in 2024 to $101.58 billion by 2029, with an average annual growth rate of 4.1% [12]. - China's laboratory analytical instrument market is expected to reach $9.28 billion in 2024, with a compound annual growth rate of 4.7% from 2024 to 2029, positioning it as the second-largest market among major economies [14]. Competitive Landscape - The high-end scientific instrument market in China has been dominated by foreign manufacturers, with over 75% of large scientific instruments in universities and research institutions being imported [18]. - Guoyi Quantum faces challenges in terms of historical accumulation, operational scale, product matrix, financial strength, market share, and brand recognition compared to established players like Thermo Fisher and Agilent [18]. Management and IPO Details - Guoyi Quantum, established in 2016, is led by a young management team, including a 1992-born chairman and general manager, He Yu, who has a PhD from the University of Science and Technology of China [21]. - The company aims to raise approximately 1.169 billion for projects related to high-end scientific instrument industrialization, quantum technology research, and application center network construction [22].

Core Viewpoint - Guoyi Quantum Technology (Hefei) Co., Ltd. has officially received acceptance for its IPO application, aiming to raise approximately 1.169 billion yuan and become the "first domestic quantum sensor stock" on the Sci-Tech Innovation Board [2] Group 1: Company Overview - Guoyi Quantum is a rare unicorn in the domestic sensor sector, leveraging core technologies from the University of Science and Technology of China to achieve breakthroughs in quantum sensing and spin resonance, disrupting the long-standing monopoly of foreign manufacturers [6] - The company’s main products include enhanced quantum sensors and high-end scientific instruments, with applications across materials science, biomedicine, industrial quality inspection, and energy exploration [6] - Guoyi Quantum has established a comprehensive product service system covering key components, scientific instruments, and industry solutions, with clients including leading companies like CATL, BYD, and BOE [6] Group 2: Shareholding Structure - As of the signing date of the prospectus, the shareholding structure of Guoyi Quantum is notably dispersed, with actual controllers He Yu and Rong Xing indirectly controlling 34.87% of the voting rights through various holding platforms [7] - If the IPO is successful, their voting rights will be diluted to 31.38%, indicating a relatively low overall shareholding ratio [7] - Major shareholders holding over 5% of shares include Keda Holdings, Shuhua Technology, and Hillhouse Capital, with respective holdings of 14.75%, 8.43%, and 6.12% [7] Group 3: Fundraising and Project Focus - The company plans to publicly issue no more than 40.01 million ordinary shares, aiming to raise approximately 1.169 billion yuan, which will be allocated to three core projects: high-end scientific instrument industrialization, quantum technology research institute construction, and application center network development [7] Group 4: Financial Performance - Guoyi Quantum has shown significant revenue growth, with revenue increasing from 151 million yuan in 2022 to 501 million yuan in 2024, representing a compound annual growth rate of 81.94% [9] - Despite the revenue growth, the company continues to face pressure on profitability, with cumulative losses exceeding 400 million yuan as of mid-2025 [11] - The company reported net losses of 129 million yuan, 146 million yuan, and 86.2 million yuan for the years 2022 to 2024, with a net loss of 75.78 million yuan in the first half of 2025 [11] Group 5: Cash Flow and R&D Investment - The company has consistently reported negative cash flow from operating activities, indicating a lack of self-sustaining cash generation capability [11] - R&D investment as a percentage of revenue remains high, at 29.78% in the first half of 2025, although it has decreased from previous years [11] Group 6: Industry Competition - The competition in the quantum technology sector is intensifying, with over 30 related companies in Hefei's "Quantum Avenue," creating a complete industrial ecosystem [13] - Guoyi Quantum faces direct competition from industry leaders like Guandun Quantum, which has a market value of 47.5 billion yuan, and Benyuan Quantum, which is also progressing with its IPO [13] - The company's ongoing losses may impact its valuation and pricing in the capital market, making it crucial to demonstrate profitability potential to succeed in its IPO [14]

Core Viewpoint - Guoyi Quantum's IPO application has been accepted, aiming to raise 1.169 billion yuan for projects focused on high-end scientific instrument industrialization, quantum technology research institute construction, and application center network development, all centered around its main business in scientific instruments [1][2]. Group 1: Company Mission and Product Offerings - Guoyi Quantum is committed to the mission of "creating instruments for the country," focusing on the independent research and industrialization of high-end scientific instruments [5]. - The company's product range includes electronic paramagnetic resonance spectrometers, scanning NV probe microscopes, field emission scanning electron microscopes (SEM), and focused ion beam electron beam dual beam microscopes (FIB-SEM), breaking the monopoly of international instrument giants in several niche areas [5]. - The electronic microscope series has become a significant revenue driver, with projected sales revenue of 246 million yuan in 2024, accounting for 50.80% of total revenue, indicating that domestic electron microscopes can compete with international brands [5]. Group 2: Financial Performance and Growth - The company has experienced rapid revenue growth, with figures rising from 151 million yuan in 2022 to 399 million yuan in 2023, and projected to reach 501 million yuan in 2024, resulting in a compound annual growth rate of 81.94% over the past three years [8]. - Despite the revenue growth, the company has not yet achieved profitability due to ongoing high levels of R&D and market investment, with R&D expenses accounting for 75.34% of revenue in 2022 and 23.13% in 2024 [8]. - As of the end of 2024, the company will have a research and development staff ratio of 31.28% and has been granted 129 authorized invention patents, contributing to the establishment of national standards in the field of quantum measurement [8]. Group 3: Fundraising and Strategic Focus - The IPO funds will be allocated to three main projects: - High-end scientific instrument industrialization project to expand existing product capacity and promote new product launches, solidifying its industrial advantages in electron microscopes and quantum measurement [9]. - Quantum technology development research institute construction project to enhance cutting-edge technology research in quantum sensing and precision measurement, maintaining technological leadership [9]. - Application center network construction project to establish domestic and international demonstration, testing, and service centers, improving customer support capabilities and brand influence, and accelerating global market expansion [9]. Group 4: Market Position and Future Outlook - In a global scientific instrument market dominated by international giants like Thermo Fisher, Danaher, and Ametek, Guoyi Quantum is gradually making inroads in strategic areas such as electron microscopy and quantum precision measurement through independent innovation [11]. - Successfully listing on the Sci-Tech Innovation Board will provide strong support for subsequent R&D expansion and market development, injecting new momentum into China's path toward self-sufficiency in high-end scientific instruments [11].

Core Viewpoint - Guoyi Quantum Technology (Hefei) Co., Ltd. has submitted its IPO application to the Shanghai Stock Exchange's Sci-Tech Innovation Board, aiming to raise 1.169 billion yuan, focusing on high-end scientific instrument development for various fields including quantum technology and advanced manufacturing [1][2]. Company Overview - Since its establishment, Guoyi Quantum has focused on the R&D of high-end scientific instruments, providing essential equipment and solutions for global universities, research institutions, and enterprises [1]. - The company has developed products such as electron paramagnetic resonance spectrometers and scanning NV probe microscopes, achieving performance metrics that meet or exceed international competitors, thereby challenging the long-standing dominance of international giants in the domestic high-end scientific instrument market [2]. Market Context - The global scientific instrument market is highly concentrated, with European and American companies dominating due to their technological advantages and brand recognition, particularly in high-precision and complex high-end instruments [1]. - Despite the growing domestic demand for high-end scientific instruments driven by rapid advancements in industries like biomedicine and semiconductors, the domestic production rate remains low, indicating a high dependency on imports [1]. Financial Overview - The company reported revenues of approximately 151 million yuan, 400 million yuan, 501 million yuan, and 171 million yuan for the years 2022, 2023, 2024, and the first half of 2025, respectively [3]. - The net profit attributable to the parent company for the same periods was -123 million yuan, -140 million yuan, -74.08 million yuan, and -72.58 million yuan, indicating ongoing financial challenges [3]. Investment Projects - The funds raised from the IPO will be allocated to several key projects, including: - High-end scientific instrument industrialization project with a total investment of 784.83 million yuan, of which 454.72 million yuan will be funded by the IPO proceeds - Quantum technology development research institute construction project with a total investment of 449.40 million yuan, fully funded by the IPO proceeds - Application center network construction project with a total investment of 264.83 million yuan, fully funded by the IPO proceeds [3]. Financial Metrics - As of June 30, 2025, the total assets are projected to be approximately 1.307 billion yuan, with equity attributable to the parent company at around 674.66 million yuan [4]. - The company has shown a trend of increasing asset-liability ratios, rising from 19.50% in 2022 to 43.75% in 2025 [4]. - R&D expenditure as a percentage of revenue was 29.78% in 2025, indicating a strong commitment to innovation despite financial losses [4].